As a specialized company dedicated to ophthalmology, Santen carries out research, development, marketing, and sales of pharmaceuticals, over-the-counter products, and devices. Santen is the market leader for prescription ophthalmic pharmaceuticals in Japan and its products now reach patients in over 60 countries. With scientific knowledge and organizational capabilities nurtured over a nearly 130-year history, Santen provides products and services to contribute to the well-being of patients, their loved ones and consequently to society.

Business Activities

Vision-driven / Customer Perspective / Creativity and Innovation / Employee Growth / Harmony with Society

Strategic Vision

Organizational Principles

Aiming to Become a “Specialized Pharmaceutical Company with a Global Presence”

Integrity and Trust / Customer-oriented Thinking / Expertise / Innovation / Collaboration and CooperationIndividual Action Principles

Guided by Santen’s Values in all our business activities, Santen strives to achieve our long-term strategic vision toward the year 2020. We provide products and services reflecting the needs of patients and medical personnel worldwide.

“Exploring the secrets and mechanisms of nature in order to contribute to people’s health”

We think carefully about what is essential, decide clearly what we should do, and act quickly.

By focusing on ophthalmology, Santen develops unique scientific knowledge and organizational capabilities that contribute to the well-being of patients, their loved ones and consequently to society.

COMPANY PROFILE

Santen’s original interpretation of a passage from chapter 22 of Zhongyong (The Doctrine of the Mean) by Confucius, meaning

Mission Statement

Values

Santen’s Values and Mission Statement

Develop products that meet true customer needs swiftly

Transform Japan business for further growth

Accelerate business expansion in Asia and promote market entry in Western Europe / U.S.

Establish global supply and quality systems

Strengthen organization and talent capabilities to promote creation and innovation

Five Policies to Achieve Vision 2020

92.3%Year ended March 31, 2019

Glaucoma / ocular hypertension

Disease area Project Compound /Product Original / Licensor Region / Country

Kerato conjunctival disease

Cataract

Retinal / uveal disease

Allergy

Myopia

tafluprost/timolol maleateomidenepag isopropylsepetaprostglaucoma implant devicelatanoprost

diquafosol sodium

sirolimuscarotuximab

ciclosporinepinastine hydrochloride

atropine sulfate

intraocular lens

Co-development with AGCCo-development with Ube IndustriesONO PHARMACEUTICALOriginalOriginal

Merck Sharp & Dohme Corp. (U.S.)

OriginalTRACON Pharmaceuticals

OriginalNippon Boehringer Ingelheim

Singapore Health Services, Nanyang Technological University

Oculentis

ChinaU.S. / Japan / AsiaU.S. / JapanU.S. / Europe Europe / Asia

China

U.S. / Japan / Europe / AsiaU.S.

Europe / Asia / OthersJapan

Japan / Asia

Japan

Business Overview

#2

Over-the-CounterPharmaceuticals

Share ofJapanese Market

Prescription Pharmaceuticals(Revenue Composition)

Medical Devices Others

Financial Information Santen Pharmaceutical Co., Ltd., and Subsidiaries (IFRS) years ended March 31, 2019

Corporate Information

Pipeline / Product Development Status ( As of May 9, 2019 )

Revenue

Core operating profit

Core net profit for the year

Operating profit

Net profit for the year

Corporate HeadquartersSanten Pharmaceutical Co., Ltd.Grand Front Osaka Tower A, 4-20 Ofuka-cho Kita-ku, Osaka 530-8552, JapanTEL: +81-6-6321-7000

Established 1890Incorporated 1925Paid-in Capital ¥8,252 million (As of Mar 31, 2019)Number of Employees 4,073 (As of Mar 31, 2019)Representatives　Akira Kurokawa (Chairman & CEO)Stock Exchange Listings　Tokyo (Ticker code : 4536)

SubsidiariesJapan : 3 subsidiaries U.S. : 7 subsidiaries EMEA : 10 subsidiaries, Santen SA （EMEA Headquarters）Asia : 11 subsidiaries

Laboratories and PlantsNara Research and Development Center Noto Plant, Shiga Product Supply CenterSuzhou Plant, Tampere Plant

234,026

48,230

36,092

45,098

31,943

EPS

R&D expenses

Depreciation and amortization

Cash dividends, applicable to the period

Thousands of U.S. Dollars Thousands of U.S. Dollars

31.4％ 20.6％ 10.2％ 4.0％ 11.1％

*1 Source: Copyright © 2019 IQVIA. IMS-JPM 2018-2019; Santen analysis based on IQVIA data. Reprinted with permission.

*2 Market share and market position in Japanese for the fiscal year ended March 31, 2019.　　Source: Santen Pharmaceutical Co., Ltd.

*3 Santen discloses information on a core basis to better express its recurring business　　performance. Financial information on a core basis excludes certain gains and expenses　　from IFRS results on a full basis.

Overseas sales to revenue Core operating profit margin*3 R&D expenses to revenue Revenue growth Return on equity (ROE)

*2 234.0

FY2018Revenue

billion yen

2,108,535

434,547

325,185

406,322

287,798

¥ 78.67

23,759

10,969

¥ 26

$ 0.71

214,061

98,831

$ 0.23

Please refer to the Pipeline sectionon the Company’s website for details.

Countries in WhichProducts Are Sold

Approximately

60Prescription Ophthalmic

Pharmaceuticals Share of

Japanese Market

1# *1

Production Sites 4 plantsNoto, Shiga (Japan),

Suzhou (China) and Tampere (Finland)

US dollar amounts have been translated for convenience only from yen at the rate of ¥110.99 to US $1.00,the exchange rate prevailing on March 31, 2019

DE-111DE-117DE-126DE-128DE-130A (Catioprost)

DE-089

DE-109DE-122

DE-076C (Vekacia)DE-114A

DE-127

MD-16

Millions of YenMillions of Yen